This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human UCH-L3 / UCHL3 Protein, His Tag
catalog :
UC3-H5141
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
UC3-H5141
product name :
Human UCH-L3 / UCHL3 Protein, His Tag
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
quantity & price :
$260/100ug,$1600/1mg (500ug × 2)
target :
UCH-L3
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human UCH-L3, His Tag (UC3-H5141) is expressed from E.coli cells. It contains AA Glu 2 - Ala 230 (Accession # P15374-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human UCH-L3, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCH-L3), a member of peptidase C12 family, is also known as ubiquitin thioesterase L3. Deubiquitinating enzyme (DUB) that controls levels of cellular ubiquitin through processing of ubiquitin precursors and ubiquitinated proteins. UCH-L3 is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of either ubiquitin or NEDD8. UCH-L3 indirectly increases the phosphorylation of IGFIR, AKT and FOXO1 and promotes insulin-signaling and insulin-induced adipogenesis. It is also required for stress-response retinal, skeletal muscle and germ cell maintenance. Furthermore, UCH-L3 may be involved in working memory and can hydrolyze UBB(+1), a mutated form of ubiquitin which is not effectively degraded by the proteasome and is associated with neurogenerative disorders.
References :
(1) Nam M.J., et al., 2003, Proteomics 3:2108-2115.
(2) Setsuie R., et al., 2009, Neurochem. Int. 54:314-321.
(3) Iphofer A., et al., 2012, ChemBioChem 13:1416-1420.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments